Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 11/20 | 0.38 |
| ▸ | CTSS | P25774 | 5/20 | 0.35 |
| ▸ | CTSK | P43235 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25843190 | 0.88 | TRPA1 (0.38) | TRPA1AAK1CTSSCTSKCA1 | |
| SCHEMBL30493109 | 0.85 | TRPA1 (0.42) | TRPA1AAK1CTSSCTSKCA1 | |
| SCHEMBL23564089 | 0.81 | TRPA1 (0.49) | TRPA1AAK1CTSSCTSKCTSB | |
| SCHEMBL26464327 | 0.76 | TRPA1 (0.41) | TRPA1AAK1CTSSCTSKCA1 | |
| SCHEMBL29945748 | 0.76 | TRPA1 (0.41) | TRPA1AAK1CTSSCTSKCA1 | |
| SCHEMBL28880364 | 0.76 | TRPA1 (0.41) | TRPA1AAK1CTSSCTSKCA1 | |
| SCHEMBL23564025 | 0.75 | TRPA1 (0.48) | TRPA1AAK1CTSSCTSKCTSB | |
| SCHEMBL24800892 | 0.74 | AAK1 (0.40) | TRPA1AAK1CTSSCTSKCA1 | |
| SCHEMBL24800893 | 0.73 | TRPA1 (0.46) | TRPA1AAK1CTSSCTSKCTSB | |
| SCHEMBL1345706 | 0.72 | GPR139 (0.43) | TRPA1AAK1CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702418-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230137886-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137886-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | TRPA1 4791/4885AAK1 1385/4885CTSS 1863/4885 |
| US-11702418-B2 | SOS1 inhibitors | SOS1, SOS2, SOST | TRPA1 4624/4885AAK1 1653/4885CTSS 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.